Catalyst Wire Dossier Catalyst Wire Dossier

Febseltiq

Infigratinib monophosphate · Helsinn Birex Pharmaceuticals Ltd
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for Febseltiq, covering 2023-01-30 to 2023-01-30. Get the full timeline:

Most recent: EMA Application withdrawn: Febseltiq (Infigratinib monophosphate) — Helsinn Birex Pharmaceuticals Ltd

See pricing